On Monday, Simcere Pharma reported sharply higher Q3 financials, but investors were not impressed, sending the stock 9% lower. However, second-thoughts on the “day after” are causing the stock to regain the entire loss and close just below $16 per share, right where it was before it released its Q3 report. By themselves, the numbers are impressive. But the numbers do no more than meet expectations, leaving investors and analysts without a happy surprise. More details...

Stock Symbol: (NYSE: SCR)